GRB10 interacting GYF protein 1Genealiases: GYF1 · PERQ1
Q-omics provides the consensus-scored GIGYF1 profile across patient tissues and cancer cell-line models. GIGYF1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GIGYF1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GIGYF1 RNA expression shows 19,778 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where GIGYF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIGYF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIGYF1 survival associations across molecular data types. GIGYF1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIGYF1 RNA expression–survival associations across cancer types. High GIGYF1 expression shows unfavorable associations in KICH, ACC and KIRC, but favorable associations in HNSC, BRCA and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GIGYF1 RNA expression.
This table summarizes GIGYF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GIGYF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIGYF1 shows higher tumor expression in HNSC, KIRP, KIRC, COAD, LIHC and STAD. The HNSC box plot shows higher GIGYF1 RNA expression in tumor versus normal tissue (log2 FC = +0.785, t-test p < 0.001).
This table shows molecular features associated with GIGYF1 in patient tissues and cancer cell lines. In patient samples, GIGYF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GIGYF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
